ResMed Inc.

ResMed Inc.

RMDยทNYSE

$186.46

+2.0%
HealthcareMedical - Devices

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME)to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; and HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies. The company markets its products primarily to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

At a Glance

Live Snapshot
Market Cap$27.05B
EPS9.5500
P/E Ratio19.52
Earnings Date07/30/2026
19.56%
Return on Invested Capital
10%
3Y+7.0%
5Y+14.0%
10Y+66.0%
23.47%
Return on Equity
12%
3Y+1.0%
5Y-6.0%
10Y+13.0%
17.14%
Return on Assets
15%
3Y+12.0%
5Y+26.0%
10Y+58.0%
ResMed Inc.

ResMed Inc. Management Team

RMD ยท NYSE
MK

Mr. Kaushik Ghoshal

Chief Commercial Officer - SaaS

Compensation

$1,230,965

Born 1969(Age 57)
male
MJ

Mr. Jim Ellis

Chief Compliance Officer

male
MM

Mr. Michael J. Farrell BE, MBA, SM

Chief Executive Officer & Chairman

Compensation

$2,974,477

Born 1972(Age 54)
male
MB

Mr. Brett A. Sandercock

Chief Financial Officer

Compensation

$971,973

Born 1967(Age 59)
male
MA

Mr. Alastair Robertson

Chief Information Officer

male
MS

Ms. Sallilyn Schwartz

Chief Investor Relations Officer

female
MM

Mr. Michael J. Rider

Chief Legal Officer & Secretary

Compensation

$889,117

Born 1958(Age 68)
male
MY

Ms. Yvonne-Katrin Pucknat

Chief Marketing Officer

Born 1976(Age 50)
female
MV

Ms. Vered Keisar

Chief People Officer

female
MJ

Mr. Justin Leong

Chief Product Officer

Compensation

$1,311,404

Born 1977(Age 49)
male
DP

Dr. Peter C. Farrell A.M., B.E., BE (Hons), Ph.D., ScD

Founder, Chair Emeritus & Director

Compensation

$459,719

Born 1942(Age 84)
DP

Dr. Peter C. Farrell A.M., B.E., BE (Hons), Ph.D., ScD

Founder, Chair Emeritus & Non-Executive Director

Compensation

$413,215

Born 1942(Age 84)
rmd

ResMed Inc. Insider Positioning

RMD ยท NYSE

During the last 12 months, insiders have sold $30.71M worth of RMD shares, with no buying activity reported.

3 Months

Bought

0

0.00

Sold

18.0K

4.09M

Net Activity

-4.1M

-$4.09M

3-6 Months

Bought

0

0.00

Sold

24.1K

6.16M

Net Activity

-6.2M

-$6.16M

6-9 Months

Bought

0

0.00

Sold

37.7K

10.00M

Net Activity

-10.0M

-$10.00M

9-12 Months

Bought

0

0.00

Sold

39.5K

10.47M

Net Activity

-10.5M

-$10.47M

Top Buyers

No buying activity

Top Sellers

1
FMJ

Farrell Michael J.

Director, Officer: Chairman And Ceo

78.0K sharesโ€ข12 transactions

$20.08M

2
SB

Sandercock Brett

Officer: Chief Financial Officer

20.9K sharesโ€ข10 transactions

$5.44M

3
FPC

Farrell Peter C

Director

14.9K sharesโ€ข8 transactions

$3.71M

4
HJ

Hernandez John

Director

2.6K sharesโ€ข1 transactions

$739K

5
DWJ

De Witte Jan

Director

2.5K sharesโ€ข2 transactions

$646K

Insider Activity Analysis

Net Insider Sentiment

Bearish

Strong bearish signal with $30.71M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.

Buy/Sell Ratio

0.00:1

Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.

Recent Trend (3 Months)

$4.09M

Heavy recent selling activity. Recent insider sales notably exceed purchasesโ€”may warrant investigation into company developments.

Insider Participation

High Selling

5 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.

Insider Activity Insight

Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.

SEC Filings

RMD - Filing history and reports

Filing TypeFiling DatePeriod EndingFiscal YearActions
DEF 14A

DEF 14A 2025

N/A

October 02, 2025
June 30, 2025
2025
DEF 14A

DEF 14A 2024

N/A

October 03, 2024
June 30, 2024
2024
DEF 14A

DEF 14A 2023

N/A

October 05, 2023
June 30, 2023
2023
DEF 14A

DEF 14A 2022

N/A

October 05, 2022
October 05, 2022
2022
DEF 14A

DEF 14A 2021

N/A

October 06, 2021
October 06, 2021
2021
DEF 14A

DEF 14A 2020

N/A

October 06, 2020
October 06, 2020
2020
DEF 14A

DEF 14A 2019

N/A

October 08, 2019
November 21, 2019
2019
DEF 14A

DEF 14A 2018

N/A

October 03, 2018
November 15, 2018
2018
DEF 14A

DEF 14A 2017

N/A

September 25, 2017
November 16, 2017
2017
DEF 14A

DEF 14A 2016

N/A

September 26, 2016
November 16, 2016
2016
Showing 1 to 10 of 31 filings